AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3203661 — intervention group
Group type: COMPARATOR
Intervention: Static exercise (holding weights without movement) at 50% maximal voluntary contraction (MVC) for 1 min.
Number of subjects: 5
Study 30819217 — intervention group
Group type: EXPERIMENTAL
Intervention: Gift card incentive group
Number of subjects: 2426
Study 30819217 — intervention group
Group type: EXPERIMENTAL
Intervention: Charity donation incentive group
Number of subjects: 2426
Study 30819217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 2426
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: pdC1‐INH
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: icatibant
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: both pdC1‐INH and icatibant
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: self-injection
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: home treatment
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: early treatment decision
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: full coverage
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: no coverage
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: partial reimbursement
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: sharing treatment dose
Number of subjects: 225
Study 28825570 — intervention group
Group type: EXPERIMENTAL
Intervention: access to medication
Number of subjects: 225
Study 26214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 via four weekly intravenous drip)
Number of subjects: 50
Study 26214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (0.02 mg/kg by intravenous drip once a week for three months)
Number of subjects: 50
Study 26214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 50
Study 26214772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine
Number of subjects: 50
Study 24007767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling intervention
Number of subjects: 211
Study 24007767 — intervention group
Group type: COMPARATOR
Intervention: Telephone reminder and barriers assessment, followed by a mailed home tailored barriers print brochure
Number of subjects: 211
Study 24007767 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care comprising telephone reminder and barriers assessment
Number of subjects: 211
Study 21261975 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) initiated within 24-48 hours after ICU admission
Number of subjects: 0
Study 21261975 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition (PN) initiated on day 8 when caloric target is not reached
Number of subjects: 0
Study 18581100 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 24
Study 18581100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16514301 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300/100 mg) QD
Number of subjects: 0
Study 16514301 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (400/100 mg) BID
Number of subjects: 0
Study 14641992 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative chemotherapy
Number of subjects: 0
Study 14641992 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant or alternative chemotherapies
Number of subjects: 0
Study 14641992 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor/tyrosine kinase inhibitor gefitinib
Number of subjects: 0
Study 14641992 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of new approaches and standard therapy
Number of subjects: 0
Study 10837389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) therapy
Number of subjects: 85
Study 10837389 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy
Number of subjects: 85
Study 10837389 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 85
Study 9428991 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warm up (AWU)
Number of subjects: 0
Study 9428991 — intervention group
Group type: COMPARATOR
Intervention: Passive warm up (PWU)
Number of subjects: 0
Study 8451470 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90
Study 8451470 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 8451470 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-Propofol combination
Number of subjects: 90
Study 2934124 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM (5‐fluorouracil, Adriamycin [doxorubicin], mitomycin)
Number of subjects: 196
Study 2934124 — intervention group
Group type: COMPARATOR
Intervention: FSM (5‐fluorouracil, streptozotocin, mitomycin)
Number of subjects: 196
Study 2934124 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM
Number of subjects: 196
Study 2934124 — intervention group
Group type: COMPARATOR
Intervention: FSM
Number of subjects: 196
Study 30080869 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported last menstrual period
Number of subjects: 4390
Study 30080869 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphysis-fundal height measurement
Number of subjects: 4390
Study 30080869 — intervention group
Group type: EXPERIMENTAL
Intervention: New Ballard Score
Number of subjects: 4390
Study 30080869 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4390
Study 26975007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual cessation (reduced smoking by 75% in 2 weeks before quitting)
Number of subjects: 697
Study 26975007 — intervention group
Group type: COMPARATOR
Intervention: Abrupt cessation (quit smoking immediately)
Number of subjects: 697
Study 26975007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual cessation
Number of subjects: 697
Study 26975007 — intervention group
Group type: COMPARATOR
Intervention: Abrupt cessation
Number of subjects: 697
Study 26975007 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who preferred gradual cessation
Number of subjects: 697
Study 26975007 — intervention group
Group type: COMPARATOR
Intervention: Participants who preferred abrupt cessation
Number of subjects: 697
Study 24408211 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg mCPP
Number of subjects: 48
Study 24408211 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg mCPP
Number of subjects: 48
Study 24408211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22266572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Number of subjects: 40
Study 22266572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20222295 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 18848575 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-light walker direction discrimination task
Number of subjects: 6
Study 18848575 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-light walker identification task
Number of subjects: 6
Study 18848575 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentricity adjustment using F=1+E/E(2)
Number of subjects: 6
Study 16115830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient held targets and self monitoring
Number of subjects: 441
Study 16115830 — intervention group
Group type: COMPARATOR
Intervention: Usual care (blood pressure monitoring by practice)
Number of subjects: 441
Study 12463426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric decompression (n = 69)
Number of subjects: 136
Study 12463426 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric decompression (n = 67)
Number of subjects: 136
Study 10526939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate infusion (isosorbide dinitrate: ISDN or nitroglycerin: TNG) for 30 minutes (group A)
Number of subjects: 0
Study 10526939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate infusion for 48 hours (group B)
Number of subjects: 0
Study 10526939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate infusion for 78 hours (group C)
Number of subjects: 0
Study 7481324 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy for high-risk tumors
Number of subjects: 0
Study 7481324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined local treatment (surgery plus radiotherapy)
Number of subjects: 0
Study 7481324 — intervention group
Group type: COMPARATOR
Intervention: Single local modality (surgery or radiotherapy)
Number of subjects: 0
Study 2261943 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 22
Study 2261943 — intervention group
Group type: COMPARATOR
Intervention: Slow-release verapamil (V)
Number of subjects: 22
Study 2261943 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E) and Slow-release verapamil (V)
Number of subjects: 22
Study 446311 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiro‐Tablinen
Number of subjects: 6
Study 446311 — intervention group
Group type: COMPARATOR
Intervention: Aldactone‐100 Caps
Number of subjects: 6
Study 31821466 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc bis-glycinate (15 mg elemental zinc), twice per day
Number of subjects: 91
Study 31821466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 31815647 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat-based diet (900g/week of meat and derivatives)
Number of subjects: 150
Study 31815647 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat-based diet supplemented with alpha-tocopherol
Number of subjects: 150
Study 31815647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pesco-vegetarian diet (450g/week of fish)
Number of subjects: 150
Study 31815647 — intervention group
Group type: COMPARATOR
Intervention: All diets (meat-based, meat-based with alpha-tocopherol, pesco-vegetarian)
Number of subjects: 150
Study 28640104 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyTube (EzT)
Number of subjects: 400
Study 28640104 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 400
Study 25888734 — intervention group
Group type: EXPERIMENTAL
Intervention: Play Streets
Number of subjects: 126
Study 25888734 — intervention group
Group type: COMPARATOR
Intervention: Control Streets
Number of subjects: 126
Study 24007754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg given by mouth)
Number of subjects: 16
Study 24007754 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated driving setting with Lorazepam
Number of subjects: 16
Study 21311047 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention (patient education, health promotion coaching, medication management, physician care management)
Number of subjects: 452
Study 19480559 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant cytochromes P450 and physiologically based pharmacokinetic modelling
Number of subjects: 10
Study 17826428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiotocography + STAN analysis
Number of subjects: 799
Study 17826428 — intervention group
Group type: COMPARATOR
Intervention: Cardiotocography
Number of subjects: 799
Study 15102733 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 185
Study 15102733 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost of neonatal ECMO
Number of subjects: 185
Study 15102733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean additional health service cost of neonatal ECMO
Number of subjects: 185
Study 11072398 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg/day nicotine patch
Number of subjects: 1039
Study 11072398 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/day nicotine patch
Number of subjects: 1039
Study 11072398 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg/day nicotine patch
Number of subjects: 1039
Study 11072398 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/day nicotine patch (control)
Number of subjects: 1039
Study 7564894 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg caffeine/kg lean body mass
Number of subjects: 39
Study 7564894 — intervention group
Group type: COMPARATOR
Intervention: No caffeine (control)
Number of subjects: 39
Study 7564894 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 39
Study 7564894 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with osteoporosis
Number of subjects: 39
Study 2207419 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium 60 mmol/day alone
Number of subjects: 37
Study 2207419 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium 60 mmol/day in combination with magnesium 20 mmol/day
Number of subjects: 37
Study 2207419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7461014 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of digoxin 1.25 mg
Number of subjects: 0
Study 7461014 — intervention group
Group type: COMPARATOR
Intervention: Loading dose of digoxin 0.625 mg
Number of subjects: 0
Study 7461014 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of digoxin 0.25 mg
Number of subjects: 0
Study 7461014 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of digoxin 0.125 mg
Number of subjects: 0
Study 31836261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin 40UI
Number of subjects: 19
Study 31836261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30199135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 61
Study 30199135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 61
Study 27888747 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus response prevention (E + RP)
Number of subjects: 0
Study 27888747 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus safety behavior (E + SB)
Number of subjects: 0
Study 27888747 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 25939742 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in a transparent laparoscopic box trainer under direct vision followed by a standard non-transparent laparoscopic box trainer (Group 1)
Number of subjects: 34
Study 25939742 — intervention group
Group type: COMPARATOR
Intervention: Training in a standard laparoscopic box trainer (Group 2)
Number of subjects: 34
Study 25939742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 24857519 — intervention group
Group type: EXPERIMENTAL
Intervention: LNAA tablets plus supplementation with tryptophan (Trp) and tyrosine (Tyr) tablets
Number of subjects: 10
Study 24857519 — intervention group
Group type: COMPARATOR
Intervention: LNAA tablets plus placebo
Number of subjects: 10
Study 23011591 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 13
Study 23011591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19651265 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercises
Number of subjects: 180
Study 19651265 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated exercises
Number of subjects: 180
Study 19651265 — intervention group
Group type: COMPARATOR
Intervention: Social visits
Number of subjects: 180
Study 17616778 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrée portion size of 500 g and energy density of 1.8 kcal/g
Number of subjects: 53
Study 17616778 — intervention group
Group type: COMPARATOR
Intervention: Entrée portion size of 250 g and energy density of 1.3 kcal/g
Number of subjects: 53
Study 15222514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and combined technique of physical therapy
Number of subjects: 122
Study 15222514 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 122
Study 11790931 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 11790931 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic ICD implantation
Number of subjects: 0
Study 9849309 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing radiographs
Number of subjects: 116
Study 9849309 — intervention group
Group type: COMPARATOR
Intervention: Supine radiographs
Number of subjects: 116
Study 7818632 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 156
Study 7818632 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 156
Study 7818632 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and plain spinal CT
Number of subjects: 156
Study 7818632 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography
Number of subjects: 156
Study 31970512 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Number of subjects: 80
Study 31970512 — intervention group
Group type: COMPARATOR
Intervention: Non-PM+ group (control)
Number of subjects: 80
Study 30627841 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-fixating mesh
Number of subjects: 270
Study 30627841 — intervention group
Group type: COMPARATOR
Intervention: Non-fixating mesh
Number of subjects: 270
Study 28069044 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-acupuncture (TEAS)
Number of subjects: 142
Study 28069044 — intervention group
Group type: COMPARATOR
Intervention: Placebo-acupuncture
Number of subjects: 142
Study 25654309 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical LVR (n = 9)
Number of subjects: 26
Study 25654309 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic LVR (n = 7)
Number of subjects: 26
Study 25654309 — intervention group
Group type: COMPARATOR
Intervention: Sham/unsuccessful bronchoscopic treatment (Control, n = 10)
Number of subjects: 26
Study 24383720 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 563
Study 24383720 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 563
Study 24383720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 22048783 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 127
Study 22048783 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 127
Study 18841473 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational booklet about stigma based on experiences of Black mental health consumers
Number of subjects: 42
Study 18841473 — intervention group
Group type: COMPARATOR
Intervention: Existing brochures about services
Number of subjects: 42
Study 17109595 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (600 microg) and biotin (2 mg/day)
Number of subjects: 43
Study 17109595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15701219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 432
Study 15701219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 432
Study 15701219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 11739451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (0.1 microg/kg.min)
Number of subjects: 12
Study 11739451 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 8988939 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention group
Number of subjects: 0
Study 8988939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 8988939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient data
Number of subjects: 0
Study 8988939 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cholesterol measurements
Number of subjects: 0
Study 8988939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-biochemical relations
Number of subjects: 0
Study 8477485 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education at a diabetes clinic with specific educational objectives.
Number of subjects: 2
Study 8477485 — intervention group
Group type: COMPARATOR
Intervention: Conventional care at general medical clinics.
Number of subjects: 2
Study 3557711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (15 micrograms/kg, intravenously)
Number of subjects: 26
Study 3557711 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg as a bolus followed by chronic infusion of 0.005 mg/kg/min for 3 min, intravenously)
Number of subjects: 26
Study 29776990 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 97
Study 29776990 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 97
Study 29776990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 27835980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Community awareness raising, training and supervision of private sector providers, regular meetings between public and private providers.
Number of subjects: 8910
Study 27835980 — intervention group
Group type: COMPARATOR
Intervention: Control: Standard care without the intervention components.
Number of subjects: 8910
Study 25338053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulfate)
Number of subjects: 282
Study 25338053 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (100% sodium chloride)
Number of subjects: 282
Study 22508203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (1.5 μg/kg body weight)
Number of subjects: 61
Study 22508203 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA with Piritramide
Number of subjects: 61
Study 20723651 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg 1 time/day
Number of subjects: 114
Study 20723651 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 114